Once-weekly semaglutide 7.2 mg in adults with obesity
The Lancet
2025
Study summary
Higher-dose semaglutide 7.2 mg was evaluated in adults with obesity.
Peptides studied
Goals studied
Stack studied
Metabolic Stack
Key findings
Higher-dose semaglutide improved weight outcomes versus placebo in the STEP UP program.
Study details
Study type
randomized clinical trial
Journal
The Lancet
DOI / PubMed
10.1016/S0140-6736(24)01448-5
Year
2025
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.